GetTopicDetailResponse(id=22ab4850622, topicName=帕納替尼, introduction=帕納替尼, content=null, image=null, comments=1, allHits=1600, url=https://h5.medsci.cn/topic?id=48506, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=16599, tagList=[TagDto(tagId=16599, tagName=帕納替尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2271634, encodeId=27d322e1634f1, content=<a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細胞白血病#</a> <a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a> <a href='/topic/show?id=066211e13968' target=_blank style='color:#2F92EE;'>#貝林妥歐單抗#</a>, objectTitle=JHO：帕納替尼聯(lián)合貝林妥歐單抗一線治療費城染色體陽性急性淋巴細胞白血病的復發(fā)分子特征與預測因子研究進展, objectType=article, longId=885017, objectId=463888501eb2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, objectUrl=/article/show_article.do?id=463888501eb2, replyNumber=0, likeNumber=23, createdTime=2025-07-01, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=463888501eb2, moduleTitle=JHO：帕納替尼聯(lián)合貝林妥歐單抗一線治療費城染色體陽性急性淋巴細胞白血病的復發(fā)分子特征與預測因子研究進展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=463888501eb2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213457, encodeId=4a39221345eb3, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一線治療#</a> <a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊馬替尼#</a> <a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細胞白血病#</a> <a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a>, objectTitle=JAMA：帕納替尼與伊馬替尼在費城染色體陽性急性淋巴細胞白血病的一線治療中的比較, objectType=article, longId=833242, objectId=5708833242dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720172627148_92910.jpg, objectUrl=/article/show_article.do?id=5708833242dc, replyNumber=0, likeNumber=117, createdTime=2024-07-05, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5708833242dc, moduleTitle=JAMA：帕納替尼與伊馬替尼在費城染色體陽性急性淋巴細胞白血病的一線治療中的比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5708833242dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1077313, encodeId=279d10e7313ea, content=<a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕納替尼#</a>模型結果表明，在美國，達沙替尼和普納替尼可被視為具有成本效益的選擇，與其他 CML 二線 TKI 相比，可提供臨床益處。, objectTitle=帕納替尼, objectType=topic, longId=48506, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=120, createdTime=2021-12-06, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
